

09/899917

=> dis his

(FILE 'HOME' ENTERED AT 17:05:56 ON 10 JAN 2003)

FILE 'BIOSIS, CAPLUS, EMBASE, MEDLINE, SCISEARCH' ENTERED AT 17:08:26 ON
10 JAN 2003

L1 2 S HUMAN (W) ONCOGENE (W) INDUCED (W) SECRET? (W) PROTEIN
L2 2 S HOIPS OR HOIPSI
L3 2 L1 AND L2
L4 2 L3 AND (POLYPEPTIDE OR PROTEIN OR FRAGMENT OR MUTANT)
L5 2 DUP REM L1 (0 DUPLICATES REMOVED)
L6 2 DUP REM L2 (0 DUPLICATES REMOVED)
L7 2 DUP REM L3 (0 DUPLICATES REMOVED)
L8 2 DUP REM L4 (0 DUPLICATES REMOVED)

=> log off y

STN INTERNATIONAL LOGOFF AT 17:19:05 ON 10 JAN 2003

STN Search Strategy

File: 09/09
09/899917
EAST Search Shelly

Type	L #	Hits	Search Text	DBS	Time Stamp	Comment s	Error Definition	Error ro rs
1	BRS	L7	32213 HOIIPS or HOIIPS I 70	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2003/01/1 0 16:18	0		
2	BRS	L26	5 L1 and (polypeptide or protein or fragment or mutant)	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2003/01/1 0 16:25	0		
3	BRS	L20	4 L1 and L13	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2003/01/1 0 16:27	0		
4	BRS	L13	4 HOIIPS	USPA T; US-P GPUB ; EPO; JPO; DERW ENT	2003/01/1 0 16:29	0		

Type	L #	Hits	Search Text	DBS	Time Stamp	Comment s	Error Definition	Error rs
5	BRS L1	5	human adj oncogene adj induced adj secret\$ adj protein	USPA	T; US-P GPUB ; 2003/01/1 0 16:30	EPO; JPO; DERW ENT	0	

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1653hxp

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * Welcome to STN International * * * * * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 Jun 03 New e-mail delivery for search results now available
NEWS 4 Aug 08 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5 Aug 19 Aquatic Toxicity Information Retrieval (AQUIRE)
now available on STN
NEWS 6 Aug 26 Sequence searching in REGISTRY enhanced
NEWS 7 Sep 03 JAPIO has been reloaded and enhanced
NEWS 8 Sep 16 Experimental properties added to the REGISTRY file
NEWS 9 Sep 16 CA Section Thesaurus available in CAPLUS and CA
NEWS 10 Oct 01 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11 Oct 24 BEILSTEIN adds new search fields
NEWS 12 Oct 24 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13 Nov 18 DKILIT has been renamed APOLLIT
NEWS 14 Nov 25 More calculated properties added to REGISTRY
NEWS 15 Dec 04 CSA files on STN
NEWS 16 Dec 17 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17 Dec 17 TOXCENTER enhanced with additional content
NEWS 18 Dec 17 Adis Clinical Trials Insight now available on STN
NEWS 19 Jan 29 Simultaneous left and right truncation added to COMPENDEX,
ENERGY, INSPEC
NEWS 20 Feb 13 CANCERLIT is no longer being updated
NEWS 21 Feb 24 METADEX enhancements
NEWS 22 Feb 24 PCTGEN now available on STN
NEWS 23 Feb 24 TEMA now available on STN
NEWS 24 Feb 26 NTIS now allows simultaneous left and right truncation
NEWS 25 Feb 26 PCTFULL now contains images
NEWS 26 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27 Mar 20 EVENTLINE will be removed from STN
NEWS 28 Mar 24 PATDPAFULL now available on STN
NEWS 29 Mar 24 Additional information for trade-named substances without
structures available in REGISTRY
NEWS 30 Apr 11 Display formats in DGENE enhanced
NEWS 31 Apr 14 MEDLINE Reload
NEWS 32 Apr 17 Polymer searching in REGISTRY enhanced
NEWS 33 Jun 13 Indexing from 1947 to 1956 added to records in CA/CAPLUS
NEWS 34 Apr 21 New current-awareness alert (SDI) frequency in
WPIDS/WPINDEX/WPIX
NEWS 35 Apr 28 RDISCLOSURE now available on STN
NEWS 36 May 05 Pharmacokinetic information and systematic chemical names
added to PHAR
NEWS 37 May 15 MEDLINE file segment of TOXCENTER reloaded
NEWS 38 May 15 Supporter information for ENCOMPPAT and ENCOMPLIT updated
NEWS 39 May 16 CHEMREACT will be removed from STN
NEWS 40 May 19 Simultaneous left and right truncation added to WSCA
NEWS 41 May 19 RAPRA enhanced with new search field, simultaneous left and
right truncation
NEWS 42 Jun 06 Simultaneous left and right truncation added to CBNB

NEWS 43 Jun 06 PASCAL enhanced with additional data
NEWS 44 Jun 20 2003 edition of the FSTA Thesaurus is now available
NEWS 45 Jun 25 HSDB has been reloaded

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 12:38:50 ON 30 JUN 2003

FILE 'MEDLINE' ENTERED AT 12:39:27 ON 30 JUN 2003

FILE 'BIOSIS' ENTERED AT 12:39:27 ON 30 JUN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'WPIDS' ENTERED AT 12:39:27 ON 30 JUN 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

FILE 'EMBASE' ENTERED AT 12:39:27 ON 30 JUN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'DGENE' ENTERED AT 12:39:27 ON 30 JUN 2003
COPYRIGHT (C) 2003 DERWENT INFORMATION LTD

FILE 'USPATFULL' ENTERED AT 12:39:27 ON 30 JUN 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> s human oncogene induced secreted protein
5 FILES SEARCHED...

24 [View All Posts](#) [View All Comments](#)

Digitized by srujanika@gmail.com

BT ANSWER 1 OF 21 BISSES COPYRIGHT 2005 BIOLOGICAL ABSTRACTS INC.
TI Human oncogene induced secreted

AB The present invention relates to

AB The present invention relates to a novel protein, the **human Oncogene Induced Secreted Protein I** ("HOIPS I") protein. In particular, isolated nucleic acid molecules are provided encoding the human HOIPS I protein. HOIPS I polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for

treating the same.

ACCESSION NUMBER: 2001:519304 BIOSIS
DOCUMENT NUMBER: PREV200100519304
TITLE: **Human oncogene induced secreted protein I.**
AUTHOR(S): Olsen, Henrik S.; Ruben, Steven M.
ASSIGNEE: Human Genome Sciences, Inc.
PATENT INFORMATION: US 6284486 September 04, 2001
SOURCE: Official Gazette of the United States Patent and Trademark Office Patents, (Sep. 4, 2001) Vol. 1250, No. 1, pp. No Pagination. e-file.
ISSN: 0098-1133.
DOCUMENT TYPE: Patent
LANGUAGE: English

L1 ANSWER 2 OF 21 WPIDS (C) 2003 THOMSON DERWENT
TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia.
AN 1998-377652 [32] WPIDS
AB WO 9828421 A UPAB: 19980812
An isolated nucleic acid molecule (I) is claimed comprising a polynucleotide (PN) having a nucleotide sequence (NS) at least 95% identical to a sequence selected from:
(a) a NS encoding a polypeptide comprising amino acids from -20 to 142, -19 to 142, or 1 to 142 of the 162 amino acid (aa) sequence given in the specification (sequence representing a **Human Oncogene Induced Secreted Protein I** (HOIPS I) polypeptide);
(b) a NS encoding a polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97825;
(c) a NS encoding a mature HOIPS I polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97825; and
(d) a NS complementary to any of the NSs in (a)-(c).
Also claimed are:
(1) an isolated Nucleic Acid Molecule (NAM) comprising a PN which hybridises under stringent hybridisation conditions (I) where the PN which hybridises does not hybridise under stringent hybridisation conditions to a PN having a NS consisting of only A residues or of only T residues;
(2) an isolated NAM comprising a PN which encodes an amino acid sequence of an epitope-bearing portion of a HOIPS I polypeptide having an amino acid sequence as in (a)-(c) above;
(3) an isolated NAM comprising a PN having a sequence at least 95% identical to a sequence selected from:
(a) a NS of a fragment of a 860 bp sequence given in the specification (encoding the HOIPS I polypeptide), where the fragment comprises at least 50 contiguous nucleotides of the 860 bp, provided that the NS is not one of the 514, 457, 413, 320, 264, and 249 sequences given in the specification; and
(b) a NS complementary to a NS as in (a);
(4) a method for making a recombinant vector comprising inserting (I) into a vector;
(5) a recombinant vector produced by a method as in (4);
(6) a method of making a recombinant host cell comprising introducing a recombinant vector as in (5) into a host cell;
(7) a recombinant host cell produced by a method as in (6);
(8) an isolated HOIPS I polypeptide having an amino acid sequence at least 95% identical to a sequence encoded by (I) or an epitope-bearing portion of the polypeptide;
(9) an isolated polypeptide comprising an epitope-bearing portion of the HOIPS I protein, where the portion is selected from a polypeptide comprising amino acid residues from -4 to 9, from 13 to 19, from 23 to 32, from 36 to 47, from 54 to 63, from 70 to 74, from 90 to 100, from 105 to

119 or from 125 to 132 of the 162 aa sequence;

(10) an isolated HOIPS I polypeptide where, except for 1 to 50 conservative amino acid substitutions, the polypeptide has a sequence selected from:

(a) amino acids from -20 to 142, 19 to 142, or 1 to 142 of the 162 aa sequence given in the specification;

(b) an amino acid sequence of the HOIPS I polypeptide having an amino acid sequence encoded by a cDNA contained in ATCC 97825;

(c) an amino acid sequence of a mature HOIPS I polypeptide having an amino acid sequence encoded by a cDNA clone contained in ATCC 97825; and

(d) an amino acid sequence of an epitope-bearing portion of any one of the polypeptides as in (a)-(c);

(11) an isolated nucleic acid encoding a polypeptide as in (10).

USE - The products can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis.

Dwg.0/3

ACCESSION NUMBER: 1998-377652 [32] WPIDS

DOC. NO. NON-CPI: N1998-295209

DOC. NO. CPI: C1998-114764

TITLE: New isolated **human oncogene induced secreted protein** -

used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia.

DERWENT CLASS: B04 D16 S03

INVENTOR(S): OLSEN, H S; RUBEN, S M

PATENT ASSIGNEE(S): (HUMA-N) HUMAN GENOME SCI INC

COUNTRY COUNT: 81

PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG

WO 9828421	A1	19980702 (199832)*	EN	71	
RW:	AT BE CH DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW				
W:	AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM GW HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW				
AU 9858027	A	19980717 (199848)			
US 6284486	B1	20010904 (200154)			
US 2002119552	A1	20020829 (200259)			

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE

WO 9828421	A1	WO 1997-US23547	19971219
AU 9858027	A	AU 1998-58027	19971219
US 6284486	B1	US 1996-33869P	19961220
	Provisional	US 1997-37388P	19970207
	Provisional	US 1997-994962	19971219
US 2002119552	A1	US 1996-33869P	19961220
	Provisional	US 1997-37388P	19970207
	Div ex	US 1997-994962	19971219
		US 2001-899917	20010709

FILING DETAILS:

PATENT NO	KIND	PATENT NO

AU 9858027	A Based on	WO 9828421

PRIORITY APPLN. INFO: US 1997-37388P 19970207; US 1996-33869P
19961220; US 1997-994962 19971219; US
2001-899917 20010709

L1 ANSWER 3 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAW69220 Protein DGENE

AB This sequence is the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAW69220 Protein DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702

71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

CROSS REFERENCES: N-PSDB: AAV44745

DESCRIPTION: **Human oncogene induced secreted protein I.**

L1 ANSWER 4 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44751 cDNA DGENE

AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (HOIPS I). HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44751 cDNA DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702

71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Expressed sequence tag C02431.

L1 ANSWER 5 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced**

secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44750 cDNA DGENE

AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (HOIPS I). HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44750 cDNA DGENE

TITLE: New isolated **human oncogene**

induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702

71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Expressed sequence tag T84854.

L1 ANSWER 6 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced**

secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44749 cDNA DGENE

AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (HOIPS I). HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44749 cDNA DGENE

TITLE: New isolated **human oncogene**

induced secreted protein - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702

71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Expressed sequence tag T92475.

L1 ANSWER 7 OF 21 DGENE (C) 2003 THOMSON DERWENT
TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44748 cDNA DGENE
AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (HOIPS I). HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.
ACCESSION NUMBER: AAV44748 cDNA DGENE
TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Expressed sequence tag T91708.

L1 ANSWER 8 OF 21 DGENE (C) 2003 THOMSON DERWENT
TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44758 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.
ACCESSION NUMBER: AAV44758 DNA DGENE
TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.
L1 ANSWER 9 OF 21 DGENE (C) 2003 THOMSON DERWENT
TI New isolated **human oncogene induced secreted protein** - used to develop products for the

diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44757 DNA DGENE

AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44757 DNA DGENE

TITLE: New isolated **human oncogene induced secreted protein - used** to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Primer for **Human oncogene induced secreted protein I.**

L1 ANSWER 10 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein - used** to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44756 DNA DGENE

AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44756 DNA DGENE

TITLE: New isolated **human oncogene induced secreted protein - used** to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Primer for **Human oncogene induced secreted protein I.**

L1 ANSWER 11 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein - used** to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44755 DNA DGENE

AB This sequence is a PCR primer for DNA encoding the **human**

oncogene induced secreted protein I
(HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44755 DNA DGENE
TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L1 ANSWER 12 OF 21 DGENE (C) 2003 THOMSON DERWENT
TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44754 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.
ACCESSION NUMBER: AAV44754 DNA DGENE
TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
DESCRIPTION: Primer for **Human oncogene induced secreted protein I**.

L1 ANSWER 13 OF 21 DGENE (C) 2003 THOMSON DERWENT
TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia
AN AAV44753 DNA DGENE
AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and

diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44753 DNA DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Primer for **Human oncogene induced secreted protein I.**

L1 ANSWER 14 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44752 DNA DGENE

AB This sequence is a PCR primer for DNA encoding the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44752 DNA DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Primer for **Human oncogene induced secreted protein I.**

L1 ANSWER 15 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44746 cDNA DGENE

AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (HOIPS I). HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44746 cDNA DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Expressed sequence tag.

L1 ANSWER 16 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44747 cDNA DGENE

AB This sequence represents an expressed sequence tag, which is specifically stated as not being contained within the DNA of the invention. The DNA of the invention encodes the **human oncogene induced secreted protein I** (HOIPS I). HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44747 cDNA DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

INVENTOR: Olsen H S; Ruben S M

PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.

PATENT INFO: WO 9828421 A1 19980702 71p

APPLICATION INFO: WO 1997-US23547 19971219

PRIORITY INFO: US 1997-37388 19970207

US 1996-33869 19961220

DOCUMENT TYPE: Patent

LANGUAGE: English

OTHER SOURCE: 1998-377652 [32]

DESCRIPTION: Expressed sequence tag AA340310.

L1 ANSWER 17 OF 21 DGENE (C) 2003 THOMSON DERWENT

TI New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as leukaemia

AN AAV44745 cDNA DGENE

AB This sequence encodes the **human oncogene induced secreted protein I** (HOIPS I) of the invention. HOIPS I can be used for treating cell proliferative diseases, particularly cancers, such as acute and chronic myelogenous leukaemias. The products can also be used for detection and diagnosis of a cell proliferative or cell differentiation disorders.

ACCESSION NUMBER: AAV44745 cDNA DGENE

TITLE: New isolated **human oncogene induced secreted protein** - used to develop products for the diagnosis and treatment of cell proliferative diseases, particularly cancers such as

leukaemia
INVENTOR: Olsen H S; Ruben S M
PATENT ASSIGNEE: (HUMA-N) HUMAN GENOME SCI INC.
PATENT INFO: WO 9828421 A1 19980702 71p
APPLICATION INFO: WO 1997-US23547 19971219
PRIORITY INFO: US 1997-37388 19970207
US 1996-33869 19961220
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: 1998-377652 [32]
CROSS REFERENCES: P-PSDB: AAW69220
DESCRIPTION: Human oncogene induced secreted protein I coding sequence.

L1 ANSWER 18 OF 21 USPATFULL
TI Method and system for providing real-time, in situ biomanufacturing process monitoring and control in response to IR spectroscopy
AB A method and system for providing real-time, biomanufacturing process monitoring and control in response to infra-red (IR) spectroscopic fingerprinting of a biomolecule. IR spectroscopy is used to fingerprint an active biomolecule in situ in a biomanufacturing process. In one embodiment, Fourier Transform Infra-red spectroscopy (FTIR) is used to determine whether an active or aged biomolecule is present in stages of a biomanufacturing process. In one preferred example, the biomanufacturing process manufactures a biomaterial in bulk. The biomanufacturing process has four stages: bioproduction, recovery, purification, and bulk storage. FTIR spectroscopy is used to monitor the optimization of each process step by providing feedback controls, and to fingerprint in real-time, in situ whether active biomolecules are present in each stage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:280105 USPATFULL
TITLE: Method and system for providing real-time, in situ biomanufacturing process monitoring and control in response to IR spectroscopy
INVENTOR(S): Naughton, Raymond A., West River, MD, UNITED STATES
Rohrer, Thomas R., Hagerstown, MD, UNITED STATES
Gentz, Reiner L., Rockville, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002155541	A1	20021024
APPLICATION INFO.:	US 2002-114469	A1	20020403 (10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-616894, filed on 14 Jul 2000, GRANTED, Pat. No. US 6395538		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157863P	19991006 (60)
	US 1999-151918P	19990901 (60)
	US 1999-144071P	19990716 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	38	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	13 Drawing Page(s)	
LINE COUNT:	2291	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 19 OF 21 USPATFULL
TI **Human oncogene induced secreted protein I**
AB The present invention relates to a novel protein, the **Human Oncogene Induced Secreted Protein** I ("HOIPS I") protein. In particular, isolated nucleic acid molecules are provided encoding the human HOIPS I protein. HOIPS I polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for treating the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:221411 USPATFULL
TITLE: **Human oncogene induced secreted protein I**
INVENTOR(S): Olsen, Henrik S., Gaithersburg, MD, UNITED STATES
Ruben, Steven M., Olney, MD, UNITED STATES
PATENT ASSIGNEE(S): Human Genome Sciences, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002119552	A1	20020829
APPLICATION INFO.:	US 2001-899917	A1	20010709 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1997-994962, filed on 19 Dec 1997, PATENTED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-33869P	19961220 (60)
	US 1997-37388P	19970207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 NEW YORK AVENUE, N.W., SUITE 600, WASHINGTON, DC, 20005-3934	
NUMBER OF CLAIMS:	16	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	2059	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 20 OF 21 USPATFULL
TI Method and system for providing real-time, in situ biomanufacturing process monitoring and control in response to IR spectroscopy
AB A method and system for providing real-time, biomanufacturing process monitoring and control in response to infra-red (IR) spectroscopic fingerprinting of a biomolecule. IR spectroscopy is used to fingerprint an active biomolecule in situ in a biomanufacturing process. In one embodiment, Fourier Transform Infra-red spectroscopy (FTIR) is used to determine whether an active or aged biomolecule is present in stages of a biomanufacturing process. In one preferred example, the biomanufacturing process manufactures a biomaterial in bulk. The biomanufacturing process has four stages: bioproduction, recovery, purification, and bulk storage. FTIR spectroscopy is used to monitor the optimization of each process step by providing feedback controls, and to fingerprint in real-time, in situ whether active biomolecules are present in each stage.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2002:122481 USPATFULL
TITLE: Method and system for providing real-time, in situ biomanufacturing process monitoring and control in response to IR spectroscopy

INVENTOR(S) : Naughton, Raymond A., West River, MD, United States
Rohrer, Thomas R., Hagerstown, MD, United States
Gentz, Reiner L., Rockville, MD, United States
PATENT ASSIGNEE(S) : Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6395538	B1	20020528
APPLICATION INFO.:	US 2000-616894		20000714 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-157863P	19991006 (60)
	US 1999-144071P	19990716 (60)
	US 1999-151918P	19990901 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Weber, Jon P.
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 27
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 13 Drawing Page(s)
LINE COUNT: 2209
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 21 OF 21 USPATFULL
TI **Human oncogene induced secreted protein I**

AB The present invention relates to a novel protein, the **Human Oncogene Induced Secreted Protein I** ("HOIPS I") protein. In particular, isolated nucleic acid molecules are provided encoding the human HOIPS I protein. HOIPS I polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. Also provided are diagnostic methods for detecting abnormal cell proliferation and differentiation disorders and therapeutic methods for treating the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2001:147697 USPATFULL
TITLE: **Human oncogene induced secreted protein I**
INVENTOR(S) : Olsen, Henrik S., Gaithersburg, MD, United States
Ruben, Steven M., Olney, MD, United States
PATENT ASSIGNEE(S) : Human Genome Sciences, Inc., Rockville, MD, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6284486	B1	20010904
APPLICATION INFO.:	US 1997-994962		19971219 (8)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Carlson, Karen Cochrane
LEGAL REPRESENTATIVE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
NUMBER OF CLAIMS: 69
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 1994
CAS INDEXING IS AVAILABLE FOR THIS PATENT.